Phaseline

Companies › Highlightll Pharmaceutical (USA)

Highlightll Pharmaceutical (USA): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HL-400
NLRP3 inflammasome inhibitor
NLRP3Phase 1Parkinson Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06997484HL-400Phase 1Parkinson DiseaseNeurologyJun 2026

Targets

NLRP3 (1)

Companies with the same targets

Olatec Therapeutics AC Immune

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.